The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients.

@article{Ede2001TheCM,
  title={The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients.},
  author={A. V. van Ede and R. Laan and H. Blom and T. Huizinga and C. Haagsma and B. Giesendorf and T. D. de Boo and L. V. D. van de Putte},
  journal={Arthritis and rheumatism},
  year={2001},
  volume={44 11},
  pages={
          2525-30
        }
}
  • A. V. van Ede, R. Laan, +5 authors L. V. D. van de Putte
  • Published 2001
  • Medicine
  • Arthritis and rheumatism
  • OBJECTIVE To study the possible relationship between the C677T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene and the toxicity and efficacy of treatment with methotrexate (MTX) in patients with rheumatoid arthritis (RA). METHODS Genotype analysis of the MTHFR gene was done in 236 patients who started MTX treatment with (n = 157) or without (n = 79) folic or folinic acid supplementation. Outcomes were parameters of efficacy of MTX treatment, patient withdrawal due to adverse… CONTINUE READING

    Paper Mentions

    OBSERVATIONAL CLINICAL TRIAL
    Methotrexate is a cornerstone in the treatment of childhood leukemia. When given in high-dose as part of the initial phase of treatment, gastrointestinal toxicity is a known problem… Expand
    ConditionsALL, Juvenile Idiopathic Arthritis

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 16 REFERENCES
    The mechanism of action of methotrexate.
    • 203